The in vitro activity of telavancin was tested against 743 predominantly antimicrobial-resistant, gram-positive isolates. Telavancin was highly active against methicillin-resistant staphylococci (MIC 90 , 0.5 to 1 g/ml), streptococci (all MICs, <0.12 g/ml), and VanB-type enterococci (all MICs, <2 g/ml). Time-kill studies demonstrated the potent bactericidal activity of telavancin.
tococci, 8 viridans group streptococci, and 212 VRE. Five reference strains (including three quality control strains and two type strains used for time-kill studies) were also tested.
Telavancin was prepared by Theravance, Inc. (South San Francisco, CA). All other antibiotics for MIC testing were supplied independently by TREK Diagnostic Systems (Cleveland, OH). Comparator agents for time-kill studies included vancomycin (Sigma Chemical Co., St. Louis, MO) and linezolid (Zyvox; Pfizer). Susceptibility tests were performed by reference broth microdilution methodology as defined by the CLSI using frozen form panels prepared by TREK Diagnostic Systems (Cleveland, OH) (3) . MICs for all streptococci were determined in panels supplemented with 2 to 5% lysed horse blood. Vancomycin and teicoplanin MIC results were used to define the resistance determinants of VRE. S. pneumoniae strains exhibiting concurrent resistance to at least three of the following agents were defined as MDRSP: cefuroxime, penicillin, tetracycline, erythromycin, or trimethoprim-sulfamethoxazole.
Time-kill experiments were performed according to CLSI (formerly NCCLS) defined methodology (12) The MIC profiles of telavancin and comparator agents against all tested isolates are summarized in Table 1 . Based upon MIC 90 comparisons, telavancin was among the mostactive agents tested against clinical strains of MRSA (MIC 90 ϭ 0.5 g/ml); all isolates were inhibited by Յ1 g/ml telavancin. Concurrent resistance to comparators had no effect on telavancin activity. Telavancin MICs for two daptomycin-nonsusceptible isolates (daptomycin MICs of 4 and 8 g/ml) were 0.5 and 0.25 g/ml. Based upon MIC 90 comparisons, daptomycin and quinupristin-dalfopristin were as potent as telavancin, followed by teicoplanin, vancomycin, gentamicin, and linezolid. Trimethoprim-sulfamethoxazole was the most-active agent tested against these strains. The telavancin MIC 90 against 74 MRSE and 17 other CoNS that were also resistant to methicillin was 1 g/ml. Based on MIC 90 comparisons, telavancin was more potent against this group of organisms than were vancomycin (MIC 90 ϭ 2 g/ml) and teicoplanin (MIC 90 ϭ 16 g/ml). Telavancin MICs against 16 teicoplanin nonsusceptible MRCoNS ranged from 0.25 to 0.5 g/ml.
All streptococci were highly susceptible to telavancin, including penicillin-intermediate and -resistant S. pneumoniae and MDRSP (MIC 90 ϭ 0.03 g/ml for all), group A and group B streptococci (MIC 90 ϭ 0.06 g/ml), and viridans group streptococci (MIC range, 0.015 to 0.06 g/ml). All streptococci were inhibited by Յ0.12 g/ml of telavancin. The activities of telavancin (MIC 90 ϭ 0.03 g/ml), vancomycin (MIC 90 ϭ 0.5 g/ ml), linezolid (MIC 90 ϭ 1 g/ml), and telithromycin (MIC 90 ϭ 0.5 g/ml) against all tested streptococci were unaffected by resistance to other agents, including the activities against MDRSP isolates with concurrent resistance to penicillin, erythromycin, trimethoprim-sulfamethoxazole, cefuroxime, and tetracycline. Some strains of MDRSP tested in this study were also nonsusceptible to other agents, including levofloxacin (5% nonsusceptible; MIC 90 ϭ 1 g/ml), clindamycin (27% nonsusceptible; MIC 90 ϭ Ͼ0.25 g/ml), and ceftriaxone (23% nonsusceptible; MIC 90 ϭ 2 g/ml).
Telavancin activity against all 212 tested VRE covered a broad MIC range (0.06 to 32 g/ml). Based upon MIC 90 comparisons, telavancin was at least 32-and 8-fold more active than vancomycin and teicoplanin, respectively, against all tested enterococci. A bimodal distribution of telavancin MICs was observed (Fig. 1) . All 32 VanB-type isolates were inhibited by Յ2 g/ml telavancin and displayed susceptibility (MIC 90 ϭ 2 g/ml) comparable to that reported for vancomycin-sensitive Telavancin quality controls for all MIC experiments were within CLSI-defined ranges: S. aureus ATCC 29213, 0.12 to 1 g/ml; S. pneumoniae ATCC 49619, 0.004 to 0.03 g/ml; and E. faecalis ATCC 29212, 0.12 to 0.5 g/ml (4). enterococci (7, 8) . Telavancin MICs were elevated against VanA-type VRE (MIC 50/90 ϭ 8 and 16 g/ml). Daptomycin and linezolid were the most-active agents tested against the 212 VRE with respective MIC 90 s of 4 and 2 g/ml. Quinupristin-dalfopristin was one of the most-active agents against vancomycin-resistant Enterococcus faecium, with an MIC 90 of 1 g/ml.
Time-kill curve study results for seven strains are presented in Table 2 . Telavancin was bactericidal (Ն3-log 10 inoculum reduction) against all three methicillin-resistant staphylococci by 8 h at Ն2ϫ MIC. Vancomycin was also bactericidal against these strains, with regrowth seen against the MRSE isolate by 24 h at 8ϫ MIC, while linezolid produced a bactericidal effect at 8ϫ MIC against two of the three strains tested by 24 h.
Telavancin was bactericidal against all tested streptococci at concentrations ranging from 2ϫ MIC (0.03 g/ml) for the MDRSP isolate to 8ϫ MIC (0.5 g/ml) for the S. pyogenes isolate. Vancomycin and linezolid were both bactericidal against two of the three tested streptococci at 8ϫ MIC. Telavancin and linezolid were both bacteriostatic against the VanB E. faecalis isolate, reducing the initial inoculum by 1.1 and 1.0 log 10 CFU/ml, respectively, at 8ϫ MIC.
Our results confirm the potent in vitro inhibitory and bactericidal activities of telavancin against important and emerging antimicrobial-resistant, gram-positive pathogens. Based upon MIC 90 comparisons, telavancin was consistently more active than vancomycin and teicoplanin against all organisms tested and showed potency equal to or greater than daptomycin and linezolid against all strain types except VanA-type VRE. These results, in concert with previously published reports, highlight the potential role of telavancin in the treatment of serious gram-positive infections and support the continued clinical evaluation of this new agent. 
